Xarostat Gold 20 Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Rosuvastatin (20 mg), and Clopidogrel (75 mg), designed for the management of cardiovascular conditions requiring antiplatelet therapy and lipid-lowering treatment. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase, reducing thromboxane A2 production and thereby preventing platelet aggregation. Clopidogrel, a P2Y12 receptor antagonist, further inhibits platelet activation and aggregation, providing a dual antiplatelet effect essential in reducing the risk of thrombotic events such as myocardial infarction and stroke. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), contributing to the prevention of atherosclerosis progression. This combination is particularly indicated for patients with established coronary artery disease, acute coronary syndrome, or those at high risk of cardiovascular events who require both lipid management and antiplatelet therapy. Xarostat Gold 20 Capsule should be administered under medical supervision with appropriate monitoring of lipid profiles, bleeding risk, and liver function. Caution is advised in patients with bleeding disorders, hepatic impairment, or hypersensitivity to any component. Adherence to prescribed dosage and lifestyle modifications enhances therapeutic outcomes.